Research progress on the correlation between lncRNA and gastric cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIU Chuanxu ¹ , YAO Zengwu ² , JIAN Mi ² , HU Jinchen ² , CUI Hongming ¹ , YU Bin ¹ , ZHAO Yang ² ,  JIANG Lixin ²

1. Medical College of Qingdao University, Qingdao, Shandong 266000, P. R. China;
2. The First Department of Gastrointestinal Surgery, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P. R. China;

Corresponding author：

JIANG Lixin, Email: jianglixin1969@hotmail.com

Keywords：

LncRNA; gastric cancer; neoadjuvant chemotherapy; chemoresistance

DOI：

10.7507/1007-9424.202105020

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To describe the research progress of long non-coding RNA (lncRNA) and gastric cancer in recent years, and to make reasonable prospect for future research direction.Method We collected a large amount of literatures on lncRNA and gastric cancer at home and abroad, and sort out various kinds of lncRNA, to make an in-depth interpretation of the relationship between lncRNA and gastric cancer and the mechanism of action, and then clarified the latest research progress.Results At present, the molecular mechanism of the occurrence and development of gastric cancer had not been fully elucidated, but current studies had shown that lncRNA (H19, HOTTIP, UCA1, MEG3, MALAT1, HULC, HOTAIR, GAPLINC, and so on) had regulatory effects at multiple levels such as epigenetics, transcription, translation, chemoresistance, and more and more lncRNA had been discovered closely related to gastric cancer.Conclusion lncRNA is closely related to the occurrence and development of gastric cancer and may be a key target for the treatment of gastric cancer in the future.

Citation： LIU Chuanxu, YAO Zengwu, JIAN Mi, HU Jinchen, CUI Hongming, YU Bin, ZHAO Yang, JIANG Lixin. Research progress on the correlation between lncRNA and gastric cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(3): 396-403. doi: 10.7507/1007-9424.202105020 Copy

1.	den Hoed CM, Kuipers EJ. Gastric cancer: How can we reduce the incidence of this disease? Curr Gastroenterol Rep, 2016, 18(7): 34.
2.	左婷婷, 郑荣寿, 曾红梅, 等. 中国胃癌流行病学现状. 中国肿瘤临床, 2017, 44(1): 52-58.
3.	Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014, 17(1): 26-33.
4.	Yang Z, Sun Y, Liu R, et al. Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer. Cancer Manag Res, 2019, 11: 6175-6184.
5.	Ke D, Li H, Zhang Y, et al. The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer. Oncotarget, 2017, 8(13): 21516-21525.
6.	Chang S, Liu J, Guo S, et al. HOTTIP and HOXA13 are oncogenes associated with gastric cancer progression. Oncol Rep, 2016, 35(6): 3577-3585.
7.	Yu J, Fang C, Zhang Z, et al. H19 rises in gastric cancer and exerts a tumor-promoting function via miR-138/ E2F2 axis. Cancer Manag Res, 2020, 12: 13033-13042.
8.	Li T, Mo X, Fu L, et al. Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget, 2016, 7(8): 8601-8612.
9.	Zhang X, Zhang W, Jiang Y, et al. Identification of functional lncRNAs in gastric cancer by integrative analysis of GEO and TCGA data. J Cell Biochem, 2019, 120(10): 17898-17911.
10.	Yu Y, Gao F, He Q, et al. lncRNA UCA1 functions as a ceRNA to promote prostate cancer progression via sponging miR143. Mol Ther Nucleic Acids, 2020, 19: 751-758.
11.	Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci, 2017, 21(17): 3850-3856.
12.	Gu L, Lu LS, Zhou DL, et al. UCA1 promotes cell proliferation and invasion of gastric cancer by targeting CREB1 sponging to miR-590-3p. Cancer Med, 2018, 7(4): 1253-1263.
13.	Qi Y, Ooi HS, Wu J, et al. MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10. Oncotarget, 2016, 7(11): 12693-12703.
14.	Xin L, Zhou Q, Yuan YW, et al. METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy. J Cancer Res Clin Oncol, 2019, 145(10): 2507-2517.
15.	Xia H, Chen Q, Chen Y, et al. The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. Oncotarget, 2016, 7(35): 56209-56218.
16.	Qian X, Zhao J, Yeung PY, et al. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci, 2019, 44(1): 33-52.
17.	Wang J, Su Z, Lu S, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta, 2018, 485: 229-233.
18.	Huang Y, Zhang J, Hou L, et al. LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res, 2017, 36(1): 194. doi: 10.1186/s13046-017-0666-2.
19.	Nie K, Deng Z, Zheng Z, et al. Identification of a 14-lncRNA signature and construction of a prognostic nomogram predicting overall survival of gastric cancer. DNA Cell Biol, 2020, 39(9): 1532-1544.
20.	Gao S, Zhao ZY, Wu R, et al. Prognostic value of long noncoding RNAs in gastric cancer: a meta-analysis. Onco Targets Ther, 2018, 11: 4877-4891.
21.	Xu W, Zhou G, Wang H, et al. Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer. Int J Cancer, 2020, 146(10): 2901-2912.
22.	Peng K, Liu R, Yu Y, et al. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer. Biomed Pharmacother, 2018, 97: 1138-1146.
23.	Peng F, Wang R, Zhang Y, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer, 2017, 16(1): 98. doi: 10.1186/s12943-017-0666-z.
24.	Xu Y, Zhang X, Hu X, et al. The effects of lncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9. Mol Med, 2018, 24(1): 52. doi: 10.1186/s10020-018-0050-5.
25.	Lian Y, Cai Z, Gong H, et al. HOTTIP: a critical oncogenic long non-coding RNA in human cancers. Mol Biosyst, 2016, 12(11): 3247-3253.
26.	Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: Roles in tumorigenesis. Biomed Pharmacother, 2020, 123: 109774. doi: 10.1016/j.biopha.2019.109774.
27.	Huang X, Gao Y, Qin J, et al. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214. Am J Physiol Gastrointest Liver Physiol, 2018, 314(5): G559-G565.
28.	Jiang N, Meng X, Mi H, et al. Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. Clin Chim Acta, 2018, 486: 26-33.
29.	Song Y, Zou L, Li J, et al. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8161-8168.
30.	Zuo Z, Hu H, Xu Q, et al. BBCancer: an expression atlas of blood-based biomarkers in the early diagnosis of cancers. Nucleic Acids Res, 2020, 48(D1): D789-D796.
31.	Zhan Y, Du L, Wang L, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Mol Cancer, 2018, 17(1): 142. doi: 10.1186/s12943-018-0893-y.
32.	Darbandi M, Darbandi S, Agarwal A, et al. Reactive oxygen species-induced alterations in H19-Igf2 methylation patterns, seminal plasma metabolites, and semen quality. J Assist Reprod Genet, 2019, 36(2): 241-253.
33.	Yörüker EE, Keskin M, Kulle CB, et al. Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer. Biomed Rep, 2018, 9(2): 181-186.
34.	Ali Akbar-Esfahani S, Karimipoor M, Bahreini F, et al. Diagnostic value of plasma long non-coding RNA HOTTIP as a non-invasive biomarker for colorectal cancer (a case- control study). Int J Mol Cell Med, Fall, 2019, 8(4): 240-247.
35.	Zhao R, Zhang Y, Zhang X, et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer, 2018, 17(1): 68. doi: 10.1186/s12943-018-0817-x.
36.	Li S, Li Y, Chen B, et al. exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. Nucleic Acids Res, 2018, 46(D1): D106-D112.
37.	Özgür E, Ferhatoğlu F, Şen F, et al. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer. Cancer Biomark, 2020, 27(1): 11-17.
38.	Aalijahan H, Ghorbian S. Long non-coding RNAs and cervical cancer. Exp Mol Pathol, 2019, 106: 7-16.
39.	Wang J, Yang K, Yuan W, et al. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit, 2018, 24: 9307-9316.
40.	Gharib E, Anaraki F, Baghdar K, et al. Investigating the diagnostic performance of HOTTIP, PVT1, and UCA1 long noncoding RNAs as a predictive panel for the screening of colorectal cancer patients with lymph node metastasis. J Cell Biochem, 2019, 120(9): 14780-14790.
41.	Fattahi S, Kosari-Monfared M, Golpour M, et al. LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: A novel approach to personalized medicine. J Cell Physiol, 2020, 235(4): 3189-3206.
42.	Diao L, Wang S, Sun Z. Long noncoding RNA GAPLINC promotes gastric cancer cell proliferation by acting as a molecular sponge of miR-378 to modulate MAPK1 expression. Onco Targets Ther, 2018, 11: 2797-2804.
43.	Xu ZY, Yu QM, Du YA, et al. Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer. Int J Biol Sci, 2013, 9(6): 587-597.
44.	Jin C, Shi W, Wang F, et al. Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget, 2016, 7(32): 51763-51772.
45.	Xu TP, Huang MD, Xia R, et al. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. J Hematol Oncol, 2014, 7: 63. doi: 10.1186/s13045-014-0063-7.
46.	Sun M, Jin FY, Xia R, et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer, 2014, 14: 319. doi: 10.1186/1471-2407-14-319.
47.	Peng W, Si S, Zhang Q, et al. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Exp Clin Cancer Res, 2015, 34(1): 79. doi: 10.1186/s13046-015-0197-7.
48.	Li Y, Tan BB, Zhao Q, et al. Tumor chemosensitivity is correlated with expression of multidrug resistance associated factors in variously differentiated gastric carcinoma tissues. Hepatogastroenterology, 2013, 60(121): 213-216.
49.	Kusumoto H, Maehara Y, Kusumoto T, et al. Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. Eur J Surg Oncol, 1988, 14(6): 685-689.
50.	Sun Y, Jiang Y, Huang J, et al. CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway. Cancer Med, 2017, 6(10): 2331-2346.
51.	Jia J, Zhan D, Li J, et al. The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells. J Cell Mol Med, 2019, 23(1): 656-669.
52.	Ge X, Cui H, Zhou Y, et al. miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep, 2017, 16(6): 9664-9670.
53.	Wang Y, Zhou P, Li P, et al. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered, 2020, 11(1): 536-546.
54.	Yin F, Zhang Q, Dong Z, et al. LncRNA HOTTIP participates in cisplatin resistance of tumor cells by regulating miR-137 expression in pancreatic cancer. Onco Targets Ther, 2020, 13: 2689-2699.
55.	Dai Q, Zhang T, Pan J, et al. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. J Cancer, 2020, 11(13): 3882-3892.
56.	Cheng C, Qin Y, Zhi Q, et al. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol, 2018, 107(Pt B): 2620-2629.
57.	Chen JS, Wang YF, Zhang XQ, et al. H19 serves as a diagnostic biomarker and up-regulation of H19 expression contributes to poor prognosis in patients with gastric cancer. Neoplasma, 2016, 63(2): 223-230.
58.	Hashad D, Elbanna A, Ibrahim A, et al. Evaluation of the role of circulating long non-coding RNA H19 as a promising novel biomarker in plasma of patients with gastric cancer. J Clin Lab Anal, 2016, 30(6): 1100-1105.
59.	周建中, 姚丽鸽, 刘卿, 等. 晚期胃癌血清长链非编码RNAH19水平与含紫杉醇方案化疗敏感性的关系. 临床肿瘤学杂志, 2017, 22(10): 896-902.
60.	Liu G, Xiang T, Wu QF, et al. Long noncoding RNA H19-derived miR-675 enhances proliferation and invasion via RUNX1 in gastric cancer cells. Oncol Res, 2016, 23(3): 99-107.
61.	Lv J, Ma L, Chen XL, et al. Downregulation of LncRNAH19 and MiR-675 promotes migration and invasion of human hepatocellular carcinoma cells through AKT/GSK-3β/Cdc25A signaling pathway. J Huazhong Univ Sci Technolog Med Sci, 2014, 34(3): 363-369.
62.	Fuka G, Kantner HP, Grausenburger R, et al. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia, 2012, 26(5): 927-933.
63.	Li H, Yu B, Li J, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget, 2014, 5(8): 2318-2329.
64.	Ye H, Liu K, Qian K. Overexpression of long noncoding RNA HOTTIP promotes tumor invasion and predicts poor prognosis in gastric cancer. Onco Targets Ther, 2016, 9: 2081-2088.
65.	Wang SS, Wuputra K, Liu CJ, et al. Oncogenic function of the homeobox A13-long noncoding RNA HOTTIP-insulin growth factor-binding protein 3 axis in human gastric cancer. Oncotarget, 2016, 7(24): 36049-36064.
66.	Luan Y, Li X, Luan Y, et al. Circulating lncRNA UCA1 promotes malignancy of colorectal cancer via the miR-143/MYO6 axis. Mol Ther Nucleic Acids, 2020, 19: 790-803.
67.	Yao F, Wang Q, Wu Q. The prognostic value and mechanisms of lncRNA UCA1 in human cancer. Cancer Manag Res, 2019, 11: 7685-7696.
68.	Wang CJ, Zhu CC, Xu J, et al. The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Mol Cancer, 2019, 18(1): 115. doi: 10.1186/s12943-019-1032-0.
69.	Rao M, Zhu Y, Cong X, et al. Knockdown of CREB1 inhibits tumor growth of human gastric cancer in vitro and in vivo. Oncol Rep, 2017, 37(6): 3361-3368.
70.	Al-Rugeebah A, Alanazi M, Parine NR. MEG3: an oncogenic long non-coding RNA in different cancers. Pathol Oncol Res, 2019, 25(3): 859-874.
71.	Dan J, Wang J, Wang Y, et al. LncRNA-MEG3 inhibits proliferation and metastasis by regulating miRNA-21 in gastric cancer. Biomed Pharmacother, 2018, 99: 931-938.
72.	Wu Y, Song Y, Xiong Y, et al. MicroRNA-21 (miR-21) promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell Physiol Biochem, 2017, 43(3): 945-958.
73.	Lu Z, Luo T, Pang T, et al. MALAT1 promotes gastric adenocarcinoma through the MALAT1/miR-181a-5p/AKT3 axis. Open Biol, 2019, 9(9): 190095.
74.	Ng L, Poon RT, Pang R. Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci, 2013, 70(19): 3631-3656.
75.	Shi D, Murty VV, Gu W. PCDH10, a novel p53 transcriptional target in regulating cell migration. Cell Cycle, 2015, 14(6): 857-866.
76.	Chen D, Liu L, Wang K, et al. The role of MALAT-1 in the invasion and metastasis of gastric cancer. Scand J Gastroenterol, 2017, 52(6-7): 790-796.
77.	Panzitt K, Tschernatsch MM, Guelly C, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology, 2007, 132(1): 330-342.
78.	Yu X, Zheng H, Chan MT, et al. HULC: an oncogenic long non-coding RNA in human cancer. J Cell Mol Med, 2017, 21(2): 410-417.
79.	Zhao Y, Guo Q, Chen J, et al. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep, 2014, 31(1): 358-364.
80.	Cui M, Xiao Z, Wang Y, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res, 2015, 75(5): 846-857.
81.	Lu Z, Xiao Z, Liu F, et al. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget, 2016, 7(1): 241-254.
82.	Sun J, Chu H, Ji J, et al. Long non-coding RNA HOTAIR modulates HLA-G expression by absorbing miR-148a in human cervical cancer. Int J Oncol, 2016, 49(3): 943-952.
83.	Luo ZF, Zhao D, Li XQ, et al. Clinical significance of HOTAIR expression in colon cancer. World J Gastroenterol, 2016, 22(22): 5254-5259.
84.	Berrondo C, Flax J, Kucherov V, et al. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One, 2016, 11(1): e0147236. doi: 10.1371/journal.pone.0147236.
85.	Xu Z, Chen H, Yang B, et al. The association of HOTAIR with the diagnosis and prognosis of gastric cancer and its effect on the proliferation of gastric cancer cells. Can J Gastroenterol Hepatol, 2019, 2019: 3076345. doi: 10.1155/2019/3076345.
86.	Dong X, He X, Guan A, et al. Long non-coding RNA Hotair promotes gastric cancer progression via miR-217-GPC5 axis. Life Sci, 2019, 217: 271-282.
87.	Luo Y, Ouyang J, Zhou D, et al. Long noncoding RNA GAPLINC promotes cells migration and invasion in colorectal cancer cell by regulating miR-34a/c-MET signal pathway. Dig Dis Sci, 2018, 63(4): 890-899.
88.	Liao S, Zhou S, Wang C. GAPLINC is a predictor of poor prognosis and regulates cell migration and invasion in osteosarcoma. Biosci Rep, 2018, 38(5): BSR20181171. doi: 10.1042/BSR20181171.
89.	Zheng Z, Zhu D, Zhao F, et al. Upregulated GAPLINC predicts a poor prognosis in bladder cancer patients and promotes tumor proliferation and invasion. Oncol Lett, 2018, 15(5): 6770-6776.
90.	Zhao J, Wang C, Liu S, et al. TGF-β1 mediates lncRNA GAPLINC expression to promote the migration and invasion of non-small cell lung cancer. Onco Targets Ther, 2019, 12: 6175-6180.
91.	周原世, 徐书婉, 关沧海, 等. 恶性肿瘤中 GAPLINC 的调控作用及其与患者预后的关系. 中华病理学杂志, 2019, 48(11): 902-905.
92.	Luo M, Liang C. LncRNA LINC00483 promotes gastric cancer development through regulating MAPK1 expression by sponging miR-490-3p. Biol Res, 2020, 53(1): 14. doi: 10.1186/s40659-020-00283-6.
93.	Hu Y, Wang J, Qian J, et al. Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. Cancer Res, 2014, 74(23): 6890-6902.

1. den Hoed CM, Kuipers EJ. Gastric cancer: How can we reduce the incidence of this disease? Curr Gastroenterol Rep, 2016, 18(7): 34.
2. 左婷婷, 郑荣寿, 曾红梅, 等. 中国胃癌流行病学现状. 中国肿瘤临床, 2017, 44(1): 52-58.
3. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014, 17(1): 26-33.
4. Yang Z, Sun Y, Liu R, et al. Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer. Cancer Manag Res, 2019, 11: 6175-6184.
5. Ke D, Li H, Zhang Y, et al. The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer. Oncotarget, 2017, 8(13): 21516-21525.
6. Chang S, Liu J, Guo S, et al. HOTTIP and HOXA13 are oncogenes associated with gastric cancer progression. Oncol Rep, 2016, 35(6): 3577-3585.
7. Yu J, Fang C, Zhang Z, et al. H19 rises in gastric cancer and exerts a tumor-promoting function via miR-138/ E2F2 axis. Cancer Manag Res, 2020, 12: 13033-13042.
8. Li T, Mo X, Fu L, et al. Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget, 2016, 7(8): 8601-8612.
9. Zhang X, Zhang W, Jiang Y, et al. Identification of functional lncRNAs in gastric cancer by integrative analysis of GEO and TCGA data. J Cell Biochem, 2019, 120(10): 17898-17911.
10. Yu Y, Gao F, He Q, et al. lncRNA UCA1 functions as a ceRNA to promote prostate cancer progression via sponging miR143. Mol Ther Nucleic Acids, 2020, 19: 751-758.
11. Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci, 2017, 21(17): 3850-3856.
12. Gu L, Lu LS, Zhou DL, et al. UCA1 promotes cell proliferation and invasion of gastric cancer by targeting CREB1 sponging to miR-590-3p. Cancer Med, 2018, 7(4): 1253-1263.
13. Qi Y, Ooi HS, Wu J, et al. MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10. Oncotarget, 2016, 7(11): 12693-12703.
14. Xin L, Zhou Q, Yuan YW, et al. METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy. J Cancer Res Clin Oncol, 2019, 145(10): 2507-2517.
15. Xia H, Chen Q, Chen Y, et al. The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. Oncotarget, 2016, 7(35): 56209-56218.
16. Qian X, Zhao J, Yeung PY, et al. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci, 2019, 44(1): 33-52.
17. Wang J, Su Z, Lu S, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta, 2018, 485: 229-233.
18. Huang Y, Zhang J, Hou L, et al. LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res, 2017, 36(1): 194. doi: 10.1186/s13046-017-0666-2.
19. Nie K, Deng Z, Zheng Z, et al. Identification of a 14-lncRNA signature and construction of a prognostic nomogram predicting overall survival of gastric cancer. DNA Cell Biol, 2020, 39(9): 1532-1544.
20. Gao S, Zhao ZY, Wu R, et al. Prognostic value of long noncoding RNAs in gastric cancer: a meta-analysis. Onco Targets Ther, 2018, 11: 4877-4891.
21. Xu W, Zhou G, Wang H, et al. Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer. Int J Cancer, 2020, 146(10): 2901-2912.
22. Peng K, Liu R, Yu Y, et al. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer. Biomed Pharmacother, 2018, 97: 1138-1146.
23. Peng F, Wang R, Zhang Y, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer, 2017, 16(1): 98. doi: 10.1186/s12943-017-0666-z.
24. Xu Y, Zhang X, Hu X, et al. The effects of lncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9. Mol Med, 2018, 24(1): 52. doi: 10.1186/s10020-018-0050-5.
25. Lian Y, Cai Z, Gong H, et al. HOTTIP: a critical oncogenic long non-coding RNA in human cancers. Mol Biosyst, 2016, 12(11): 3247-3253.
26. Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: Roles in tumorigenesis. Biomed Pharmacother, 2020, 123: 109774. doi: 10.1016/j.biopha.2019.109774.
27. Huang X, Gao Y, Qin J, et al. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214. Am J Physiol Gastrointest Liver Physiol, 2018, 314(5): G559-G565.
28. Jiang N, Meng X, Mi H, et al. Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. Clin Chim Acta, 2018, 486: 26-33.
29. Song Y, Zou L, Li J, et al. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8161-8168.
30. Zuo Z, Hu H, Xu Q, et al. BBCancer: an expression atlas of blood-based biomarkers in the early diagnosis of cancers. Nucleic Acids Res, 2020, 48(D1): D789-D796.
31. Zhan Y, Du L, Wang L, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Mol Cancer, 2018, 17(1): 142. doi: 10.1186/s12943-018-0893-y.
32. Darbandi M, Darbandi S, Agarwal A, et al. Reactive oxygen species-induced alterations in H19-Igf2 methylation patterns, seminal plasma metabolites, and semen quality. J Assist Reprod Genet, 2019, 36(2): 241-253.
33. Yörüker EE, Keskin M, Kulle CB, et al. Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer. Biomed Rep, 2018, 9(2): 181-186.
34. Ali Akbar-Esfahani S, Karimipoor M, Bahreini F, et al. Diagnostic value of plasma long non-coding RNA HOTTIP as a non-invasive biomarker for colorectal cancer (a case- control study). Int J Mol Cell Med, Fall, 2019, 8(4): 240-247.
35. Zhao R, Zhang Y, Zhang X, et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer, 2018, 17(1): 68. doi: 10.1186/s12943-018-0817-x.
36. Li S, Li Y, Chen B, et al. exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. Nucleic Acids Res, 2018, 46(D1): D106-D112.
37. Özgür E, Ferhatoğlu F, Şen F, et al. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer. Cancer Biomark, 2020, 27(1): 11-17.
38. Aalijahan H, Ghorbian S. Long non-coding RNAs and cervical cancer. Exp Mol Pathol, 2019, 106: 7-16.
39. Wang J, Yang K, Yuan W, et al. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit, 2018, 24: 9307-9316.
40. Gharib E, Anaraki F, Baghdar K, et al. Investigating the diagnostic performance of HOTTIP, PVT1, and UCA1 long noncoding RNAs as a predictive panel for the screening of colorectal cancer patients with lymph node metastasis. J Cell Biochem, 2019, 120(9): 14780-14790.
41. Fattahi S, Kosari-Monfared M, Golpour M, et al. LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: A novel approach to personalized medicine. J Cell Physiol, 2020, 235(4): 3189-3206.
42. Diao L, Wang S, Sun Z. Long noncoding RNA GAPLINC promotes gastric cancer cell proliferation by acting as a molecular sponge of miR-378 to modulate MAPK1 expression. Onco Targets Ther, 2018, 11: 2797-2804.
43. Xu ZY, Yu QM, Du YA, et al. Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer. Int J Biol Sci, 2013, 9(6): 587-597.
44. Jin C, Shi W, Wang F, et al. Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget, 2016, 7(32): 51763-51772.
45. Xu TP, Huang MD, Xia R, et al. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. J Hematol Oncol, 2014, 7: 63. doi: 10.1186/s13045-014-0063-7.
46. Sun M, Jin FY, Xia R, et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer, 2014, 14: 319. doi: 10.1186/1471-2407-14-319.
47. Peng W, Si S, Zhang Q, et al. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Exp Clin Cancer Res, 2015, 34(1): 79. doi: 10.1186/s13046-015-0197-7.
48. Li Y, Tan BB, Zhao Q, et al. Tumor chemosensitivity is correlated with expression of multidrug resistance associated factors in variously differentiated gastric carcinoma tissues. Hepatogastroenterology, 2013, 60(121): 213-216.
49. Kusumoto H, Maehara Y, Kusumoto T, et al. Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. Eur J Surg Oncol, 1988, 14(6): 685-689.
50. Sun Y, Jiang Y, Huang J, et al. CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway. Cancer Med, 2017, 6(10): 2331-2346.
51. Jia J, Zhan D, Li J, et al. The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells. J Cell Mol Med, 2019, 23(1): 656-669.
52. Ge X, Cui H, Zhou Y, et al. miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep, 2017, 16(6): 9664-9670.
53. Wang Y, Zhou P, Li P, et al. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered, 2020, 11(1): 536-546.
54. Yin F, Zhang Q, Dong Z, et al. LncRNA HOTTIP participates in cisplatin resistance of tumor cells by regulating miR-137 expression in pancreatic cancer. Onco Targets Ther, 2020, 13: 2689-2699.
55. Dai Q, Zhang T, Pan J, et al. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. J Cancer, 2020, 11(13): 3882-3892.
56. Cheng C, Qin Y, Zhi Q, et al. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol, 2018, 107(Pt B): 2620-2629.
57. Chen JS, Wang YF, Zhang XQ, et al. H19 serves as a diagnostic biomarker and up-regulation of H19 expression contributes to poor prognosis in patients with gastric cancer. Neoplasma, 2016, 63(2): 223-230.
58. Hashad D, Elbanna A, Ibrahim A, et al. Evaluation of the role of circulating long non-coding RNA H19 as a promising novel biomarker in plasma of patients with gastric cancer. J Clin Lab Anal, 2016, 30(6): 1100-1105.
59. 周建中, 姚丽鸽, 刘卿, 等. 晚期胃癌血清长链非编码RNAH19水平与含紫杉醇方案化疗敏感性的关系. 临床肿瘤学杂志, 2017, 22(10): 896-902.
60. Liu G, Xiang T, Wu QF, et al. Long noncoding RNA H19-derived miR-675 enhances proliferation and invasion via RUNX1 in gastric cancer cells. Oncol Res, 2016, 23(3): 99-107.
61. Lv J, Ma L, Chen XL, et al. Downregulation of LncRNAH19 and MiR-675 promotes migration and invasion of human hepatocellular carcinoma cells through AKT/GSK-3β/Cdc25A signaling pathway. J Huazhong Univ Sci Technolog Med Sci, 2014, 34(3): 363-369.
62. Fuka G, Kantner HP, Grausenburger R, et al. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia, 2012, 26(5): 927-933.
63. Li H, Yu B, Li J, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget, 2014, 5(8): 2318-2329.
64. Ye H, Liu K, Qian K. Overexpression of long noncoding RNA HOTTIP promotes tumor invasion and predicts poor prognosis in gastric cancer. Onco Targets Ther, 2016, 9: 2081-2088.
65. Wang SS, Wuputra K, Liu CJ, et al. Oncogenic function of the homeobox A13-long noncoding RNA HOTTIP-insulin growth factor-binding protein 3 axis in human gastric cancer. Oncotarget, 2016, 7(24): 36049-36064.
66. Luan Y, Li X, Luan Y, et al. Circulating lncRNA UCA1 promotes malignancy of colorectal cancer via the miR-143/MYO6 axis. Mol Ther Nucleic Acids, 2020, 19: 790-803.
67. Yao F, Wang Q, Wu Q. The prognostic value and mechanisms of lncRNA UCA1 in human cancer. Cancer Manag Res, 2019, 11: 7685-7696.
68. Wang CJ, Zhu CC, Xu J, et al. The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Mol Cancer, 2019, 18(1): 115. doi: 10.1186/s12943-019-1032-0.
69. Rao M, Zhu Y, Cong X, et al. Knockdown of CREB1 inhibits tumor growth of human gastric cancer in vitro and in vivo. Oncol Rep, 2017, 37(6): 3361-3368.
70. Al-Rugeebah A, Alanazi M, Parine NR. MEG3: an oncogenic long non-coding RNA in different cancers. Pathol Oncol Res, 2019, 25(3): 859-874.
71. Dan J, Wang J, Wang Y, et al. LncRNA-MEG3 inhibits proliferation and metastasis by regulating miRNA-21 in gastric cancer. Biomed Pharmacother, 2018, 99: 931-938.
72. Wu Y, Song Y, Xiong Y, et al. MicroRNA-21 (miR-21) promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell Physiol Biochem, 2017, 43(3): 945-958.
73. Lu Z, Luo T, Pang T, et al. MALAT1 promotes gastric adenocarcinoma through the MALAT1/miR-181a-5p/AKT3 axis. Open Biol, 2019, 9(9): 190095.
74. Ng L, Poon RT, Pang R. Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci, 2013, 70(19): 3631-3656.
75. Shi D, Murty VV, Gu W. PCDH10, a novel p53 transcriptional target in regulating cell migration. Cell Cycle, 2015, 14(6): 857-866.
76. Chen D, Liu L, Wang K, et al. The role of MALAT-1 in the invasion and metastasis of gastric cancer. Scand J Gastroenterol, 2017, 52(6-7): 790-796.
77. Panzitt K, Tschernatsch MM, Guelly C, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology, 2007, 132(1): 330-342.
78. Yu X, Zheng H, Chan MT, et al. HULC: an oncogenic long non-coding RNA in human cancer. J Cell Mol Med, 2017, 21(2): 410-417.
79. Zhao Y, Guo Q, Chen J, et al. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep, 2014, 31(1): 358-364.
80. Cui M, Xiao Z, Wang Y, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res, 2015, 75(5): 846-857.
81. Lu Z, Xiao Z, Liu F, et al. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget, 2016, 7(1): 241-254.
82. Sun J, Chu H, Ji J, et al. Long non-coding RNA HOTAIR modulates HLA-G expression by absorbing miR-148a in human cervical cancer. Int J Oncol, 2016, 49(3): 943-952.
83. Luo ZF, Zhao D, Li XQ, et al. Clinical significance of HOTAIR expression in colon cancer. World J Gastroenterol, 2016, 22(22): 5254-5259.
84. Berrondo C, Flax J, Kucherov V, et al. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One, 2016, 11(1): e0147236. doi: 10.1371/journal.pone.0147236.
85. Xu Z, Chen H, Yang B, et al. The association of HOTAIR with the diagnosis and prognosis of gastric cancer and its effect on the proliferation of gastric cancer cells. Can J Gastroenterol Hepatol, 2019, 2019: 3076345. doi: 10.1155/2019/3076345.
86. Dong X, He X, Guan A, et al. Long non-coding RNA Hotair promotes gastric cancer progression via miR-217-GPC5 axis. Life Sci, 2019, 217: 271-282.
87. Luo Y, Ouyang J, Zhou D, et al. Long noncoding RNA GAPLINC promotes cells migration and invasion in colorectal cancer cell by regulating miR-34a/c-MET signal pathway. Dig Dis Sci, 2018, 63(4): 890-899.
88. Liao S, Zhou S, Wang C. GAPLINC is a predictor of poor prognosis and regulates cell migration and invasion in osteosarcoma. Biosci Rep, 2018, 38(5): BSR20181171. doi: 10.1042/BSR20181171.
89. Zheng Z, Zhu D, Zhao F, et al. Upregulated GAPLINC predicts a poor prognosis in bladder cancer patients and promotes tumor proliferation and invasion. Oncol Lett, 2018, 15(5): 6770-6776.
90. Zhao J, Wang C, Liu S, et al. TGF-β1 mediates lncRNA GAPLINC expression to promote the migration and invasion of non-small cell lung cancer. Onco Targets Ther, 2019, 12: 6175-6180.
91. 周原世, 徐书婉, 关沧海, 等. 恶性肿瘤中 GAPLINC 的调控作用及其与患者预后的关系. 中华病理学杂志, 2019, 48(11): 902-905.
92. Luo M, Liang C. LncRNA LINC00483 promotes gastric cancer development through regulating MAPK1 expression by sponging miR-490-3p. Biol Res, 2020, 53(1): 14. doi: 10.1186/s40659-020-00283-6.
93. Hu Y, Wang J, Qian J, et al. Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. Cancer Res, 2014, 74(23): 6890-6902.

Previous Article
Gastrointestinal complications after cardiac surgery
Next Article
Anterior mediastinal inflammatory myofibroblastic tumor with thymoma: A case report

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress on the correlation between lncRNA and gastric cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content